Guillaume Mabilleau - Search Results

Year	Number of Results
2006	1
2008	6
2009	1
2010	1
2011	4
2012	3
2013	7
2014	7
2015	9
2016	3
2017	7
2018	5
2019	5
2020	5
2021	4
2022	1
2023	6
2024	3

1

Acetoacetate protects macrophages from lactic acidosis-induced mitochondrial dysfunction by metabolic reprograming.

Adam C, Paolini L, Gueguen N, Mabilleau G, Preisser L, Blanchard S, Pignon P, Manero F, Le Mao M, Morel A, Reynier P, Beauvillain C, Delneste Y, Procaccio V, Jeannin P. Adam C, et al. Among authors: mabilleau g. Nat Commun. 2021 Dec 8;12(1):7115. doi: 10.1038/s41467-021-27426-x. Nat Commun. 2021. PMID: 34880237 Free PMC article.

2

Predicting Bone Regeneration with a Simple Blood Test.

Mabilleau G, Delneste Y, Papon N. Mabilleau G, et al. Trends Mol Med. 2021 Jul;27(7):622-623. doi: 10.1016/j.molmed.2021.03.006. Epub 2021 Mar 30. Trends Mol Med. 2021. PMID: 33811008 Review.

3

Incretins and bone: friend or foe?

Mabilleau G. Mabilleau G. Curr Opin Pharmacol. 2015 Jun;22:72-8. doi: 10.1016/j.coph.2015.03.007. Epub 2015 Apr 29. Curr Opin Pharmacol. 2015. PMID: 25917551 Review.

4

Novel skeletal effects of glucagon-like peptide-1 (GLP-1) receptor agonists.

Mabilleau G, Pereira M, Chenu C. Mabilleau G, et al. J Endocrinol. 2018 Jan;236(1):R29-R42. doi: 10.1530/JOE-17-0278. Epub 2017 Aug 30. J Endocrinol. 2018. PMID: 28855317 Free article. Review.

5

Update on: effects of anti-diabetic drugs on bone metabolism.

Mabilleau G, Bouvard B. Mabilleau G, et al. Expert Rev Endocrinol Metab. 2020 Nov;15(6):415-430. doi: 10.1080/17446651.2020.1831911. Epub 2020 Oct 16. Expert Rev Endocrinol Metab. 2020. PMID: 33059497 Review.

6

Osteomorphs as a tool for personalized medicine.

Mabilleau G, Libouban H, Geoffroy V. Mabilleau G, et al. Trends Endocrinol Metab. 2021 Sep;32(9):655-656. doi: 10.1016/j.tem.2021.04.004. Epub 2021 Apr 22. Trends Endocrinol Metab. 2021. PMID: 33895074

7

Narrative Review of Effects of Glucagon-Like Peptide-1 Receptor Agonists on Bone Health in People Living with Obesity.

Herrou J, Mabilleau G, Lecerf JM, Thomas T, Biver E, Paccou J. Herrou J, et al. Among authors: mabilleau g. Calcif Tissue Int. 2024 Feb;114(2):86-97. doi: 10.1007/s00223-023-01150-8. Epub 2023 Nov 24. Calcif Tissue Int. 2024. PMID: 37999750 Review.

8

Incretin-based therapy for the treatment of bone fragility in diabetes mellitus.

Mabilleau G, Gobron B, Bouvard B, Chappard D. Mabilleau G, et al. Peptides. 2018 Feb;100:108-113. doi: 10.1016/j.peptides.2017.12.008. Peptides. 2018. PMID: 29412811 Free article. Review.

9

Use of GLP-1 mimetic in type 2 diabetes mellitus: is it the end of fragility fractures?

Mabilleau G. Mabilleau G. Endocrine. 2015 Feb;48(1):1-2. doi: 10.1007/s12020-014-0461-1. Epub 2014 Oct 28. Endocrine. 2015. PMID: 25348148 No abstract available.

10

Development of a First-in-Class Unimolecular Dual GIP/GLP-2 Analogue, GL-0001, for the Treatment of Bone Fragility.

Gobron B, Couchot M, Irwin N, Legrand E, Bouvard B, Mabilleau G. Gobron B, et al. Among authors: mabilleau g. J Bone Miner Res. 2023 May;38(5):733-748. doi: 10.1002/jbmr.4792. Epub 2023 Mar 9. J Bone Miner Res. 2023. PMID: 36850034 Free article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

67 results

Results by year

Search Page

Filters

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

Search Results

67 results

Results by year